6 assets in Congenital Amegakaryocytic Thrombocytopenia

Therapeutic assets addressing Congenital Amegakaryocytic Thrombocytopenia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Congenital Amegakaryocytic Thrombocytopenia	Fred Hutchinson Cancer Center	P2	BB (71)
Thiotepa Congenital Amegakaryocytic Thrombocytopenia	Fred Hutchinson Cancer Center	P2	BB (64)
Methotrexate Congenital Amegakaryocytic Thrombocytopenia	Fred Hutchinson Cancer Center	P2	B (62)
Tacrolimus Congenital Amegakaryocytic Thrombocytopenia	Fred Hutchinson Cancer Center	P2	B (61)
Treosulfan Congenital Amegakaryocytic Thrombocytopenia	Fred Hutchinson Cancer Center	P2	B (57)
Lapine T-Lymphocyte Immune Globulin Congenital Amegakaryocytic Thrombocytopenia	Fred Hutchinson Cancer Center	P2	CCC (48)